Markets by TradingView

Browsing Tag

cardiol

13 posts

The Growing Market for Recurrent Pericarditis Therapies

Recurrent pericarditis management has evolved significantly in recent years, with treatment approaches…

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Toronto, Ontario–(Newsfile Corp. – April 16, 2025) – Cardiol Therapeutics Inc. (NASDAQ: CRDL)…

From $1 to $8? Why Analyst Experts Are Bullish on Cardiol

Sometimes stock market performance doesn’t line up with the fundamentals of a…

Small Pharma, Big Gains: The Power of Clinical Trial Results

For smaller pharmaceutical companies, valuation can be greatly impacted by progression in…

These Healthcare Stocks Significantly Outperformed the Industry in 2024

While the stock market broadly experienced significant gains in 2024, a few…

Cardiol Execs and Board Members Increase Equity, Signal Confidence

Members of the Cardiol Therapeutics Inc. (Nasdaq: CRDL) (TSX: CRDL) executive team…

Cardiol’s Favorable Phase 2 Results Set the Table for Advanced Clinical Trials

Cardiol Therapeutics Inc. (Nasdaq: CRDL) (TSX: CRDL) recently presented excellent results from…

Cardiol Therapeutics’ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the…

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1…